Antibody Polymer Conjugate

Service Description

Antibody polymer conjugates (APCs) are one of the key tools in biopharmaceutical R&D. As a specialty biotechnology company, BOC Sciences provides customized antibody polymer conjugate services designed to provide advanced solutions for researchers, pharmaceutical professionals, and clinical laboratories. Our goal is to help users gain a deeper understanding of disease mechanisms and develop more targeted therapeutics by providing more efficient tools.

What is Antibody Polymer Conjugate?

Antibody polymer conjugates are an innovative form of drug that conjugates monoclonal antibodies to biopolymers to improve drug targeting, potency, and stability. This conjugate enables precise delivery of therapeutic drugs to target cells or tissues through the specific recognition capabilities of antibodies, while enhancing the pharmacokinetic performance of the drug using polymers. Key benefits of APCs include:

Improved Targeting: Antibodies are highly specific, and by binding to the target antigen, the drug only acts on specific cells or tissues, increasing the precision and efficacy of treatment.

Reduced Side Effects: Since the effect of the drug is limited to the target tissue, APCs significantly reduce damage to healthy tissue, which in turn reduces adverse effects.

Improved Drug Stability and Persistence: Polymer chains can extend the half-life of a drug in the body, allowing it to maintain efficacy for a longer period of time, thereby reducing the frequency of administration.

Reduced Costs: Polymer conjugation enables the integration of multiple therapeutic molecules in a single drug formulation, reducing drug production steps and reducing development and manufacturing costs.

Applications of Antibody Polymer Conjugate

The wide range of applications for antibody-polymer conjugates covers a wide range of areas, including but not limited to:

Tumor Treatment: APCs achieve efficient drug delivery by targeting specific antigens on the surface of tumor cells, reducing damage to healthy cells.

Anti-infective Therapy: Using the recognition ability of antibodies, antibiotics or antiviral drugs can be accurately delivered to the infection lesion to improve the treatment effect.

Inflammatory and Immune Diseases: APCs can be used to modulate the immune response, target specific immune cells, and reduce the side effects of systemic immunosuppression.

Ophthalmic Diseases: For example, antibody-polymer conjugation technology can be used to extend the duration of drugs in the eye and effectively treat retinal diseases.

Drug Delivery: Development of novel carrier systems for the delivery of anticancer drugs, antibody-drug conjugates, and other biologics.

For example, KSI-301 is an anti-VEGF biologics that improves the persistence of the drug in eye tissue through antibody-polymer conjugation technology for the treatment of retinal vascular disease and the prevention of vision loss in patients with diabetic eye disease. The development of this technology has revolutionized several therapeutic areas, including oncology, inflammation, and chronic diseases.

Fig.1 Research progress on recombinant protein polymer-antibody conjugates for biomedicine. (Goncalves, Antonio G., et al., 2022)

Our Services

BOC Sciences offers a full range of antibody polymer conjugate services, including but not limited to:

Customized Antibody Polymer Design and Synthesis: Based on the needs of our customers, we provide customized antibody-polymer conjugation solutions to meet the goals of different research and clinical applications.

Multifunctional Drug Conjugate Development: We can conjugate multiple drugs to antibodies through polymer platforms, providing the possibility of multiplex targeted therapies.

Polymer Selection & Optimization: Our team of experts will optimize the type and structure of polymers to improve drug stability, potency, and biodistribution based on specific application scenarios.

Process Development & Scale-up: We provide complete solutions from laboratory R&D to large-scale production to ensure that projects run smoothly.

Drug Metabolism & Safety Analysis: Through robust analytical techniques, we provide quantitative assessment of drug metabolism and in vivo distribution to support safety and efficacy studies in drug development.

Our Competitive Advantages

BOC Sciences has leading technology and experience in the field of antibody polymer conjugate services. Our competitive advantages are reflected in the following aspects:

Advanced Technology Platform: We use the most cutting-edge antibody conjugation and polymer chemistry technologies to ensure the precision and control of conjugation reactions, providing efficient and stable drug conjugates.

Expert Team: Our team has extensive experience in the field of biopharmaceuticals and antibody conjugation, and is able to support our customers from basic research to application development.

Customized Service: According to the specific needs of customers, we provide flexible customized services to ensure that the project objectives are best achieved.

Strict Quality Control: We implement strict quality control processes at every R&D and production stage to ensure the stability and safety of our products.

Rapid Response and Delivery: Relying on efficient processes and advanced technical means, we are able to provide high-quality solutions in a short period of time and accelerate the progress of our customers' projects.

Case Study

Case Study 1

Antibody-drug conjugates (ADCs) are the most effective active tumor-targeting drugs used in clinical practice. However, the fabrication of ADCs with high drug-to-antibody ratios (DARs) remains a significant challenge. Herein, a Fab non-destructive SN38-loaded antibody-polymer-drug conjugate, aPDL1-NPLG-SN38, was prepared for the first time by increasing the number of payload binding sites by carboxyl group, with a DAR of up to 72 poly(L-glutamate) (PLG) groups for the first time. The binding of the Fc-III-4C peptide to PLG-graft-mPEG/SN38 (Fc-NPLG-SN38) is achieved by a click reaction between the azide and DBCO groups. The aPDL1-NPLG-SN38 conjugate is then synthesized by a high-affinity interaction between the Fc-III-4C peptide in Fc-NPLG-SN38 and the crystallizable fragment (Fc) of the PDL1 monoclonal antibody (aPDL1). This approach avoids potentially deleterious effects on the Fab structure of monoclonal antibodies. The aqueous environment used in its preparation helps to maintain monoclonal antibody recognition. By the specific recognition of PDL1 highly expressed on MC38 tumors by aPDL1, aPDL1-NPLG-SN38 accumulates 2.8-fold more in tumors than IgG-NPLG-SN38 without active tumor targeting ability. aPDL1-NPLG-SN38 exhibits excellent therapeutic properties in both medium and large MC38 tumor animal models.

Fig.2 Preparation of DAR PDL1 monoclonal antibody-polymer conjugate for the treatment of colon cancer. (Zhang, Honglei, et al., 2023)

Case Study 2

The constituent cells of the blood-brain barrier can highly express a variety of receptors and transporters, such as transferrin receptors, choline transporters, etc. Therefore, Wang et al. synthesized a polymer-antibody conjugate containing phosphocholine (MPC), in which the immune checkpoint blocking antibody anti-PD-L1 is conjugated to the polymer side group by a pH-responsive dimethylmaleic anhydride. Transport mediated by the specific binding of choline transporters to MPC enables the delivery of anti-PD-L1 across the blood-brain barrier to glioma sites. Furthermore, in the acidic microenvironment of tumors, dimethylmaleic anhydride was hydrolyzed, and the structure of anti-PD-L1 released did not change, so as to achieve traceless modification and rapid release. In this work, a glioma model with a high degree of malignancy was established, and the ability of the system to deliver drugs across the blood-brain barrier was verified at the in vitro and in vivo levels, respectively. After screening the components with the best delivery capacity, anti-glioma immunotherapy was carried out. The results showed that due to the high degree of malignancy, the control group without MPC was unable to effectively deliver antibodies to the lesion, and the mice died quickly, while the experimental group significantly prolonged the survival time of the mice.

Fig.3 Anti-PD-L1 polymer-antibody conjugate for glioma immunotherapy. (Wang, Hairong, et al., 2022)

FAQ

1. Can antibody polymer conjugates be customized for specific research needs?

Of course. BOC Sciences offers customized antibody-polymer conjugation services to ensure that the appropriate conjugation strategy is designed to optimize the performance and efficacy of the drug based on the client's research goals and needs.

2. How does antibody polymer conjugation improve drug delivery?

Antibody-polymer conjugates precisely deliver drugs to target tissues through the targeting of antibodies, and use the stability of the polymers to improve the persistence of the drug in vivo. This design can significantly improve the efficiency of drug delivery and treatment outcomes.

3. What types of diseases can benefit from antibody polymer conjugates?

Antibody polymer conjugates have a wide range of applications in oncology, immunological diseases, infectious diseases, and other fields, especially in therapies that require high targeting and reduced side effects, such as cancer, rheumatoid arthritis, and diabetic retinopathy.

4. What are the advantages of using antibody polymer conjugates over traditional antibody therapies?

Compared to traditional antibody therapies, antibody polymer conjugates have higher targeting, drug stability, and extended in vivo duration. These advantages can help lower drug doses, reduce side effects, and improve treatment outcomes.

5. What are Polymer Antibody Conjugates?

Polymer antibody conjugates are complex biomolecules formed by covalently linking antibodies to polymer carriers, enhancing the stability and targeted delivery of therapeutic agents while improving overall efficacy and reducing off-target effects.